ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2026
Protective Effects of Pomiferin on Aluminum Chloride-induced Memory Impairment: Evidence from Behavioral, Biochemical, and Insilico Studies.
Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This investigation aims to assess the neuroprotective effect of pomiferin against aluminum chloride (AlCl₃)-induced memory dysfunction in rats. Wistar rats (180 ± 20 g; 10–12 weeks old) were randomly divided into four groups (n = 8) and treated over 47 days. Group I received normal saline (control), and Group II was administered AlCl₃ (100 mg/kg, p.o.) to induce neurotoxicity. In comparison, Groups III and IV received pomiferin (10 and 20 mg/kg, p.o., respectively) once daily for 42 consecutive days, administered orally 1 h prior to AlCl₃ during the morning session to ensure optimal absorption and assess its preventive neuroprotective potential. To assess spatial and working memory performance, behavioral evaluations were conducted using the Morris Water Maze on day 42 and the Y-maze test on day 47 of the experimental period. Subsequently, biochemical analyses were performed to measure acetylcholinesterase (AChE), choline acetyltransferase (ChAT), acetylcholine (ACh), γ-aminobutyric acid (GABA), glutamate, glutathione (GSH), superoxide dismutase (SOD), malondialdehyde (MDA), catalase (CAT), nitric oxide (NO), tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), brain-derived neurotrophic factor (BDNF), caspase-3, cAMP response element-binding protein (CREB), peroxisome proliferator-activated receptor gamma (PPAR-γ), and p38 mitogen-activated protein kinase (p38 MAPK) levels. Additionally, histopathological analyses, molecular docking, and molecular dynamics simulations (MDS) were carried out. AlCl₃ induced substantial alterations in biochemical, neuroinflammatory, and neuronal enzymatic parameters, as well as in brain histology. However, these changes were ameliorated by pomiferin, accompanied by the regulation of apoptotic markers. Furthermore, pomiferin significantly improved working and spatial memory in behavioral paradigms. Furthermore, pomiferin demonstrated favorable binding affinities to target proteins, including TNF-α (-8.831 kcal/mol), CREB (-8.101 kcal/mol), caspase-3 (-7.624 kcal/mol), and BDNF (-7.080 kcal/mol). Additionally, MDS demonstrated significant conformational changes induced by pomiferin, resulting in a more favorable binding affinity to TNF-α and CREB. In conclusion, pomiferin exhibits promising neuroprotective potential in experimental models of neurodegeneration induced by AlCl₃.
Indexed as
Identifiers
42062632What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.